Upregulation of E2F transcription factor 3 is associated with poor prognosis in hepatocellular carcinoma
E2F transcription factor 3 (E2F3), a member of the E2F transcription factor family and a member of the genes involved in the regulation of cell cycle, is an oncogene with strong proliferative potential. E2F3 is involved in many processes and plays important roles in the development
of several types of cancer, while its relationship with prognosis in hepatocellular carcinoma (HCC) has yet to be reported. In the present study, based on 4 independent microarray data sets which covered 385 cases of HCC and 327 cases of normal livers retrieved from the Oncomine
database, we demonstrated that E2F3 was upregulated at least 1.5-fold and on average 2.3-fold in HCC when compared with normal controls. Comprehensive bioinformatics analysis consisting of protein-protein interaction, gene co-occurrence, microRNA-mRNA interaction and biological process annotation
indicated that E2F3 interacted with a large number of genes, proteins and microRNAs which were all associated with poor prognosis in patients with HCC and other types of cancer, suggesting that E2F3 may also serve as a biomarker for poor prognosis. Taken together, for the first time, we show
that the overexpression of E2F3 may be associated with unfavorable prognosis in HCC.
Document Type: Research Article
Affiliations: 1: Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China 2: Centre for Translational Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China 3: The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi 530021, P.R. China 4: Department of Epidemiology and Health Statistics, School of Public Health, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China 5: Guangxi Zhuang Autonomous Region Centre for Disease Prevention and Control, Nanning, Guangxi 530021, P.R. China
Publication date: 01 March 2014
- Oncology Reports is a monthly, peer-reviewed journal devoted to the publication of high quality original studies and reviews concerning a broad and comprehensive view of fundamental and applied research in oncology, focusing on carcinogenesis, metastasis and epidemiology.
The journal is published in both print and electronic format. - Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content